From Wikipedia, the free encyclopedia
Tazomeline
Clinical data
ATC code
  • None
Identifiers
  • 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard ( EPA)
Chemical and physical data
FormulaC14H23N3S2
Molar mass297.48 g·mol−1
3D model ( JSmol)
  • n2snc(/C1=C/CCN(C)C1)c2SCCCCCC

Tazomeline (LY-287,041) is a drug which acts as a non- selective muscarinic acetylcholine receptor agonist. [1] [2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons. [1] [2] [3] Another of the patented uses is for the treatment of "severe painful conditions".

See also

References

  1. ^ a b Langmead CJ, Watson J, Reavill C (February 2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics. 117 (2): 232–43. doi: 10.1016/j.pharmthera.2007.09.009. PMID  18082893.
  2. ^ a b Amos D Korczyn (October 2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs. 9 (10): 2259–2267(9). doi: 10.1517/13543784.9.10.2259. PMID  11060805. S2CID  32214700.
  3. ^ Mashkovskii MD, Glushkov RG (April 2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal. 35 (4): 179–182. doi: 10.1023/A:1010474325601. S2CID  39866378.
Retrieved from " https://en.wikipedia.org/?title=Tazomeline&oldid=1217263561"